Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05727891 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Tonabersat for DME
A Phase 2 study of Diabetic Macular Edema, sponsored by Jaeb Center for Health Research.
- Active
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
- 20
- Study locations
NCT05727891 is a Phase 2 study of Diabetic Macular Edema that is active but no longer recruiting, run by Jaeb Center for Health Research. The registered enrollment target is 128 participants, below the 3,792-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT05727891, a Phase 2 study of Diabetic Macular Edema, is active but no longer recruiting, sponsored by Jaeb Center for Health Research.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Tonabersat
Study Locations (20)
California
- Retina Associates of Southern California - Huntington Beach
- Loma Linda University - Loma Linda
- East Bay Retina Consultants, Inc. - Oakland
- Southern California Desert Retina Consultants, Inc. - Palm Desert
- Macula Retina Vitreous Institute - Torrance
Florida
- National Ophthalmic Research Institute - Fort Myers
- University of Florida- Jacksonville - Jacksonville
- Central Florida Retina Institute - Lakeland
- Florida Retina Consultants - Lakeland
- Southeast Eye Institute, P.A. dba Eye Associates of Pinellas - Pinellas Park
Georgia
- Southeast Retina Center - Augusta
- Thomas Eye Group - Sandy Springs
Massachusetts
- Boston Medical Center Corporation - Boston
- Joslin Diabetes Center - Boston
Illinois
- Illinois Retina Associates - Oak Park
Indiana
- Midwest Eye Institute - Indianapolis
Louisiana
- Joseph E. Humble and Raymond Haik PTRS DBA Eye Assoc of Northeast Louisiana - West Monroe
Maryland
- Elman Retina Group - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2026-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05727891
The ClinicalTrials.gov registry entry for NCT05727891 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,792-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (97% lower). The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05727891 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05727891 about?
NCT05727891 is a clinical study titled "Evaluation of Tonabersat for DME". This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.
What is the current status of trial NCT05727891?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2023-05-02. Estimated completion is 2026-01.
What conditions does trial NCT05727891 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT05727891?
The interventions under investigation include: Placebo (OTHER), Tonabersat (DRUG).
Who is sponsoring clinical trial NCT05727891?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05727891 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
RECRUITING · Phase 2
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
ACTIVE NOT RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
COMPLETED · Phase 2
-
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.